Lipid 8|CAS 2226547-25-5|DC Chemicals

Cas No.:	2226547-25-5
Chemical Name:	Lipid 8
Synonyms:	2-[Di-(9Z,12Z)-9,12-octadecadien-1-ylamino]ethyl 4-(dimethylamino)butanoate
SMILES:	CCCCC/C=C\C/C=C\CCCCCCCCN(CCOC(=O)CCCN(C)C)CCCCCCCC/C=C\C/C=C\CCCCC
Formula:	C₄₄H₈₂N₂O₂
M.Wt:	671.13
Purity:	>95%
Publication:	Dual-Targeted Lipid Nanotherapeutic Boost for Chemo-Immunotherapy of Cancer-Adv. Mater. 2022, 34, 2106350

Description:

Lipid 8 is a novel ionizable lipid for siRNA and mRNA delivery.Lipid 8 iLNPs were used to deliver CRISPR-Cas9 mRNA and sgRNA which targeted to the PLK1 gene. The safety and excellent intracerebral diffusion performance of lipid 8 iLNPs ensured that the survival of murine glioblastoma multiforme (GBM) mice was extended. The median survival was extended by approximately 50% and the overall survival was increased by 30%. The treatment of metastatic adenocarcinoma was executed by the EGFRtargeted lipid 8 iLNPs. These iLNPs possessed the ability of tumor targeting, which could increase the accumulation of CRISPR-Cas9 mRNA and sgRNA within the tumor cells. After a single intraperitoneal administration, 80% PLK1 gene was edited and the overall survival of mice with high-grade ovarian cancer malignant ascites was enhanced by 80% . These results demonstrate the clinical potential of CRISPR-Cas9 gene editing system can be delivered by iLNPs for treating tumors, and provide new ideas for tumor gene therapy.

References:

Dual-Targeted Lipid Nanotherapeutic Boost for Chemo-Immunotherapy of Cancer-Adv. Mater. 2022, 34, 2106350

MSDS

Cat. No.	Product name	Field of application
DC67218	Moderna Lipid compound 182	Moderna Lipid Compound 182 is a novel ionizable amine lipid developed by Moderna for the delivery of mRNA-based therapeutics. This lipid is part of Moderna's proprietary lipid nanoparticle (LNP) delivery platform, which is designed to encapsulate and protect mRNA, facilitate its cellular uptake, and enable efficient intracellular release. The ionizable nature of Lipid Compound 182 allows it to interact with mRNA at low pH (during LNP formulation) and release the payload in the neutral pH environment of the cytoplasm, making it a critical component of Moderna's mRNA delivery system.
DC67215	Acuitas Lipid III-7	Acuitas Lipid III-7 is an novel ionizable amine lipid used for mRNA delivery from Acuitas Therapeutics patent US 10,166,298 B2.
DC67214	Acuitas II-12	Acuitas II-12 is an novel ionizable amine lipid used for mRNA delivery from Acuitas Therapeutics patent WO2016176330A1
DC67213	Acuitas II-10	Acuitas II-10 is an novel ionizable amine lipid used for mRNA delivery from Acuitas Therapeutics patent WO2016176330A1
DC67212	Acuitas Lipid III-25	Acuitas Lipid III-25 is an novel ionizable amine lipid used for mRNA delivery from Acuitas Therapeutics patent US 10,166,298 B2. It is an analgous of ALC-0315, showing higher activity than ALC-0315.
DC60706	Lipid FO-35	FO-35 is an artificial intelligence-guided designed ionizable lipid for RNA delivery to the muscle, lung and nose. FO-35 LNPs enable potent transfection throughout the whole ferret lung epithelium, from trachea to alveoli.
DC60705	Lipid FO-32	FO-32 is an artificial intelligence-guided designed ionizable lipid for RNA delivery to the muscle, lung and nose. FO-32 LNPs enable potent transfection throughout the whole ferret lung epithelium, from trachea to alveoli.
DC67126	80-O18	80-O18 is a lipidoid known for its exceptional ability to enhance overall cellular uptake, showcasing significant potential as an effective delivery agent.
DC67117	113-N16B	113-N16B is an ionizable cationic lipid used for the generation of lipid nanoparticles (LNPs). 113-N16B delivers mRNA preferentially to pulmonary endothelial cells.
DC60663	Si5-N14	Si5-N14 is a lipid-based molecule engineered with siloxane groups, designed specifically for efficient mRNA delivery to the lungs. The incorporation of siloxane units boosts the cellular uptake of mRNA-loaded lipid nanoparticles (LNPs) and enhances their ability to escape from endosomes. These properties significantly increase the overall effectiveness of mRNA delivery, making Si5-N14 a promising tool for targeted therapeutic applications.